방출 제어 약물전달 시장 규모, 점유율, 동향 분석 보고서 : 기술별, 방출 기구별, 용도별, 지역별, 부문 예측(2025-2033년)

Controlled Release Drug Delivery Market Summary

The global controlled release drug delivery market size was estimated at USD 59.8 billion in 2024 and is projected to reach USD 148.6 billion by 2033, growing at a CAGR of 10.7% from 2025 to 2033. Changing prescription patterns of physicians preferring controlled-release drug delivery over conventional systems, owing to the benefits such as high therapeutic efficacy, better patient compliance, and reduced treatment cost, is expected to contribute to the market's growth over the forecast period.

Moreover, being a part of a highly competitive and fragmented market, pharmaceutical companies are proactive with the changing market requirements and continuously invest in developing controlled-release drug delivery systems, thereby significantly driving the demand.

Constantly rising R&D expenditure by pharmaceutical development companies focused on developing efficient therapy for chronic and non-communicable complications such as cancer, diabetes, and hypertension is expected to boost the market growth over the forecast period. For instance, Major pharmaceutical companies such as AbbVie, AstraZeneca, and Merck are implementing controlled drug release systems to enhance the treatment of chronic diseases, cancer, and neurological disorders.

The rising global geriatric and pediatric population is one of the major factors contributing to market growth, largely due to non-adherence to the medicine regimen, which is very common among these age groups. Geriatric populations suffer from compromised physical, mental, and biological functions that affect their medication intake. Also, their bodies cannot tolerate high doses and harsh drug side effects. Thus, the demand for controlled-release drug delivery systems is expected to grow with a steeply rising patient population.

Constantly rising R&D expenditure by pharmaceutical development companies focused on developing efficient therapies for chronic and non-communicable complications such as cancer, diabetes, and hypertension is expected to boost the market growth over the forecast period. For instance, Major pharmaceutical companies such as AbbVie, AstraZeneca, and Merck are implementing controlled drug release systems to enhance the treatment of chronic diseases, cancer, and neurological disorders.

The rising geriatric and pediatric population globally is one of the major factors contributing to market growth, largely due to non-adherence to the medicine regimen, which is very common among these age groups. Geriatric populations suffer from compromised physical, mental, and biological functions that affect their medication intake. Also, their bodies cannot tolerate high doses and the harsh side effects of drugs. Thus, the demand for controlled-release drug delivery systems is expected to grow with a steeply rising patient population.

Controlled release drug delivery significantly reduces dose and dosage frequency, prevents abnormal fluctuations of plasma drug levels, improves efficacy, enhances patient compliance, and achieves a uniform drug effect of the administered drug. Compared to traditional delivery systems, the controlled-release drug delivery systems achieve a prolonged therapeutic effect, delivering the drug at the target site at a pre-determined rate and with predictable drug release kinetics. Thus, with several added benefits offered by the controlled release delivery system, their adoption is expected to increase notably over the forecast period.

Global Controlled Release Drug Delivery Market Report Segmentation

This report forecasts country-level revenue growth and analyzes the latest industry trends and opportunities in each sub-segment from 2021 to 2033. For this study, Grand View Research has segmented the global controlled release drug delivery market report based on technology, release mechanism, and region:

• Technology Outlook (Revenue, USD Million, 2021 - 2033)
• Wurster Technique
• Coacervation
• Micro Encapsulation
• Implants
• Transdermal
• Targeted Delivery
• Others (Microelectromechanical Technology, Liposomes)
• Release Mechanism Outlook (Revenue, USD Million, 2021 - 2033)
• Polymer Based Systems
• Micro Reservoir Partition Controlled Drug Delivery Systems
• Feedback Regulated Drug Delivery Systems
• Activation-modulated Drug Delivery Systems
• Chemically Activated
• Activation-modulated Drug Delivery Systems Outlook (Revenue, USD Million, 2021 - 2033)
• Osmotic Pressure Activated
• Hydrodynamic Pressure Activated
• Vapor Pressure Activated
• Mechanically Activated
• Magnetically Activated
• Chemically Activated (Revenue, USD Million, 2021 - 2033)
• pH Activated
• Hydrolysis Activated
• Enzyme Activated
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Metered Dose Inhalers
• Injectable
• Transdermal and Ocular Patches
• Infusion Pumps
• Oral Controlled-Drug Delivery Systems
• Drug-Eluting Stents
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Netherland
  • Switzerland
  • Russia
  • Belgium
  • Sweden
• Asia Pacific
  • China
  • Japan
  • India
  • Thailand
  • South Korea
  • Indonesia
  • Philippines
  • Vietnam
  • Singapore
  • Malaysia
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Chile
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait
  • Israel

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Technology
  • 1.1.2. Release mechanism
  • 1.1.3. Application
  • 1.1.4. Estimates and forecast timeline
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased database
  • 1.3.2. GVR's internal database
  • 1.3.3. Secondary sources
  • 1.3.4. Primary research
  • 1.3.5. Details of primary research
    • 1.3.5.1. Data for primary interviews in North America
    • 1.3.5.2. Data for primary interviews in Europe
    • 1.3.5.3. Data for primary interviews in Asia Pacific
    • 1.3.5.4. Data for primary interviews in Latin America
    • 1.3.5.5. Data for Primary interviews in MEA
• 1.4. Information or Data Analysis
  • 1.4.1. Data analysis models
• 1.5. Market Formulation & Validation
• 1.6. Model Details
  • 1.6.1. Commodity flow analysis (Model 1)
    • 1.6.1.1. Approach 1: Commodity flow approach
  • 1.6.2. Volume price analysis (Model 2)
    • 1.6.2.1. Approach 2: Volume price analysis
• 1.7. List of Secondary Sources
• 1.8. List of Primary Sources
• 1.9. Objectives
  • 1.9.1. Objective 1
  • 1.9.2. Objective 2

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Technology outlook
  • 2.2.2. Release mechanism outlook
  • 2.2.3. Application outlook
  • 2.2.4. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Controlled Release Drug Delivery Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Industry Value Chain Analysis
  • 3.3.1. Reimbursement framework
• 3.4. Market Dynamics
  • 3.4.1. Market driver analysis
    • 3.4.1.1. Increase in need for controlled release dosage forms for pediatric and geriatric populations
    • 3.4.1.2. Increased compliance due to the nature of dosage forms
  • 3.4.2. Market restraint analysis
    • 3.4.2.1. Limited amount of controlled-release dosage forms is acceptable for usage in pediatric conditions
    • 3.4.2.2. Need for high dose of active pharmaceutical ingredient
• 3.5. Controlled Release Drug Delivery Market Analysis Tools
  • 3.5.1. Industry Analysis - Porter's
    • 3.5.1.1. Supplier power
    • 3.5.1.2. Buyer power
    • 3.5.1.3. Substitution threat
    • 3.5.1.4. Threat of new entrant
    • 3.5.1.5. Competitive rivalry
  • 3.5.2. PESTEL Analysis
    • 3.5.2.1. Political landscape
    • 3.5.2.2. Technological landscape
    • 3.5.2.3. Economic landscape
    • 3.5.2.4. Social landscape
    • 3.5.2.5. Environmental landscape
    • 3.5.2.6. Legal landscape
  • 3.5.3. Major Deals & Strategic Alliances Analysis
  • 3.5.4. Market Entry Strategies

Chapter 4. Global Controlled-Release Drug Delivery Market: Technology Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Controlled Release Drug Delivery Market: Technology Movement Analysis
• 4.3. Controlled Release Drug Delivery Market by Technology Outlook (USD Million)
• 4.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 4.5. Wurster Technique
  • 4.5.1. Wurster Technique Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.6. Coacervation
  • 4.6.1. Coacervation Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.7. Micro Encapsulation
  • 4.7.1. Micro Encapsulation Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.8. Implants
  • 4.8.1. Implants Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.9. Transdermal
  • 4.9.1. Transdermal Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.10. Others (Microelectromechanical Technology, Liposomes)
  • 4.10.1. Others (Microelectromechanical Technology, Liposomes) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Global Controlled-Release Drug Delivery Market: Release Mechanism Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Controlled Release Drug Delivery Market: Release Mechanism Movement Analysis
• 5.3. Controlled Release Drug Delivery Market by Release Mechanism Outlook (USD Million)
• 5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 5.5. Polymer Matrix-Based Systems
  • 5.5.1. Polymer Matrix-Based Systems Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.6. Micro Reservoir Partition Controlled Drug Delivery Systems
  • 5.6.1. Micro Reservoir Partition Controlled Drug Delivery Systems Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.7. Feedback Regulated Drug Delivery Systems
  • 5.7.1. Feedback Regulated Drug Delivery Systems Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.8. Activation-modulated Drug Delivery Systems
  • 5.8.1. Activation-modulated Drug Delivery Systems Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.8.1.1. Osmotic Pressure Activated
      • 5.8.1.1.1. Osmotic Pressure Activated Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.8.1.2. Hydrodynamic Pressure Activated
      • 5.8.1.2.1. Hydrodynamic Pressure Activated Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.8.1.3. Vapor Pressure Activated
      • 5.8.1.3.1. Vapor Pressure Activated Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.8.1.4. Mechanically Activated
      • 5.8.1.4.1. Mechanically Activated Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.8.1.5. Magnetically Activated
      • 5.8.1.5.1. Magnetically Activated Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.9. Chemically Activated
  • 5.9.1. Chemically Activated Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.9.1.1. pH Activated
      • 5.9.1.1.1. pH Activated Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.9.1.2. Hydrolysis Activated
      • 5.9.1.2.1. Hydrolysis Activated Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.9.1.3. Enzyme Activated
      • 5.9.1.3.1. Enzyme Activated Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Global Controlled-Release Drug Delivery Market: Application Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Controlled Release Drug Delivery Market: Application Movement Analysis
• 6.3. Controlled Release Drug Delivery Market by Application Outlook (USD Million)
• 6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 6.5. Metered Dose Inhalers
  • 6.5.1. Metered Dose Inhalers Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.6. Injectable
  • 6.6.1. Injectable Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.7. Transdermal and Ocular Patches
  • 6.7.1. Transdermal and Ocular Patches Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.8. Infusion Pumps
  • 6.8.1. Infusion Pumps Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.9. Oral Controlled-Drug Delivery Systems
  • 6.9.1. Oral Controlled-Drug Delivery Systems Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.10. Drug Eluting Stents
  • 6.10.1. Drug Eluting Stents Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Global Controlled-Release Drug Delivery Market: Regional Estimates & Trend Analysis

• 7.1. Regional Dashboard
• 7.2. Regional Controlled Release Drug Delivery Market Movement Analysis
• 7.3. Controlled-Release Drug Delivery Market: Regional Estimates & Trend Analysis by Product & End-use
• 7.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 7.5. North America
  • 7.5.1. North America Controlled Release Drug Delivery Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.2. U.S.
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Competitive Scenario
    • 7.5.2.3. Regulatory Framework
    • 7.5.2.4. Reimbursement scenario
    • 7.5.2.5. U.S. Controlled Release Drug Delivery Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.3. Canada
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Competitive Scenario
    • 7.5.3.3. Regulatory Framework
    • 7.5.3.4. Reimbursement scenario
    • 7.5.3.5. Canada Controlled Release Drug Delivery Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.4. Mexico
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. Competitive Scenario
    • 7.5.4.3. Regulatory Framework
    • 7.5.4.4. Reimbursement scenario
    • 7.5.4.5. Mexico Controlled Release Drug Delivery Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.6. Europe
  • 7.6.1. Europe Controlled Release Drug Delivery Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.2. UK
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Competitive Scenario
    • 7.6.2.3. Regulatory Framework
    • 7.6.2.4. Reimbursement scenario
    • 7.6.2.5. UK Controlled Release Drug Delivery Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.3. Germany
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Competitive Scenario
    • 7.6.3.3. Regulatory Framework
    • 7.6.3.4. Reimbursement scenario
    • 7.6.3.5. Germany Controlled Release Drug Delivery Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.4. France
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. Competitive Scenario
    • 7.6.4.3. Regulatory Framework
    • 7.6.4.4. Reimbursement scenario
    • 7.6.4.5. France Controlled Release Drug Delivery Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.5. Italy
    • 7.6.5.1. Key Country Dynamics
    • 7.6.5.2. Competitive Scenario
    • 7.6.5.3. Regulatory Framework
    • 7.6.5.4. Reimbursement scenario
    • 7.6.5.5. Italy Controlled Release Drug Delivery Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.6. Spain
    • 7.6.6.1. Key Country Dynamics
    • 7.6.6.2. Competitive Scenario
    • 7.6.6.3. Regulatory Framework
    • 7.6.6.4. Reimbursement scenario
    • 7.6.6.5. Spain Controlled Release Drug Delivery Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.7. Denmark
    • 7.6.7.1. Key Country Dynamics
    • 7.6.7.2. Competitive Scenario
    • 7.6.7.3. Regulatory Framework
    • 7.6.7.4. Reimbursement scenario
    • 7.6.7.5. Denmark Controlled Release Drug Delivery Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.8. Sweden
    • 7.6.8.1. Key Country Dynamics
    • 7.6.8.2. Competitive Scenario
    • 7.6.8.3. Regulatory Framework
    • 7.6.8.4. Reimbursement scenario
    • 7.6.8.5. Sweden Controlled Release Drug Delivery Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.9. Norway
    • 7.6.9.1. Key Country Dynamics
    • 7.6.9.2. Competitive Scenario
    • 7.6.9.3. Regulatory Framework
    • 7.6.9.4. Reimbursement scenario
    • 7.6.9.5. Norway Controlled Release Drug Delivery Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.7. Asia Pacific
  • 7.7.1. Asia Pacific Controlled Release Drug Delivery Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.2. Japan
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Competitive Scenario
    • 7.7.2.3. Regulatory Framework
    • 7.7.2.4. Reimbursement scenario
    • 7.7.2.5. Japan Controlled Release Drug Delivery Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.3. China
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. Competitive Scenario
    • 7.7.3.3. Regulatory Framework
    • 7.7.3.4. Reimbursement scenario
    • 7.7.3.5. China Controlled Release Drug Delivery Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.4. India
    • 7.7.4.1. Key Country Dynamics
    • 7.7.4.2. Competitive Scenario
    • 7.7.4.3. Regulatory Framework
    • 7.7.4.4. Reimbursement scenario
    • 7.7.4.5. India Controlled Release Drug Delivery Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.5. South Korea
    • 7.7.5.1. Key Country Dynamics
    • 7.7.5.2. Competitive Scenario
    • 7.7.5.3. Regulatory Framework
    • 7.7.5.4. Reimbursement scenario
    • 7.7.5.5. South Korea Controlled Release Drug Delivery Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.6. Australia
    • 7.7.6.1. Key Country Dynamics
    • 7.7.6.2. Competitive Scenario
    • 7.7.6.3. Regulatory Framework
    • 7.7.6.4. Reimbursement scenario
    • 7.7.6.5. Australia Controlled Release Drug Delivery Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.7. Thailand
    • 7.7.7.1. Key Country Dynamics
    • 7.7.7.2. Competitive Scenario
    • 7.7.7.3. Regulatory Framework
    • 7.7.7.4. Reimbursement scenario
    • 7.7.7.5. Thailand Controlled Release Drug Delivery Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.8. Latin America
  • 7.8.1. Latin America Controlled Release Drug Delivery Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8.2. Brazil
    • 7.8.2.1. Key Country Dynamics
    • 7.8.2.2. Competitive Scenario
    • 7.8.2.3. Regulatory Framework
    • 7.8.2.4. Reimbursement scenario
    • 7.8.2.5. Brazil Controlled Release Drug Delivery Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8.3. Argentina
    • 7.8.3.1. Key Country Dynamics
    • 7.8.3.2. Competitive Scenario
    • 7.8.3.3. Regulatory Framework
    • 7.8.3.4. Reimbursement scenario
    • 7.8.3.5. Argentina Controlled Release Drug Delivery Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.9. Middle East & Africa
  • 7.9.1. Middle East & Africa Controlled Release Drug Delivery Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.9.2. South Africa
    • 7.9.2.1. Key Country Dynamics
    • 7.9.2.2. Competitive Scenario
    • 7.9.2.3. Regulatory Framework
    • 7.9.2.4. Reimbursement scenario
    • 7.9.2.5. South Africa Controlled Release Drug Delivery Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.9.3. Saudi Arabia
    • 7.9.3.1. Key Country Dynamics
    • 7.9.3.2. Competitive Scenario
    • 7.9.3.3. Regulatory Framework
    • 7.9.3.4. Reimbursement scenario
    • 7.9.3.5. Saudi Arabia Controlled Release Drug Delivery Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.9.4. UAE
    • 7.9.4.1. Key Country Dynamics
    • 7.9.4.2. Competitive Scenario
    • 7.9.4.3. Regulatory Framework
    • 7.9.4.4. Reimbursement scenario
    • 7.9.4.5. UAE Controlled Release Drug Delivery Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.9.5. Kuwait
    • 7.9.5.1. Key Country Dynamics
    • 7.9.5.2. Competitive Scenario
    • 7.9.5.3. Regulatory Framework
    • 7.9.5.4. Reimbursement scenario
    • 7.9.5.5. Kuwait Controlled Release Drug Delivery Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Market Participant Categorization
• 8.2. Key Company Profiles
  • 8.2.1. Johnson & Johnson
    • 8.2.1.1. Company overview
    • 8.2.1.2. Financial performance
    • 8.2.1.3. Product benchmarking
    • 8.2.1.4. Strategic initiatives
  • 8.2.2. Pfizer Inc.
    • 8.2.2.1. Company overview
    • 8.2.2.2. Financial performance
    • 8.2.2.3. Product benchmarking
    • 8.2.2.4. Strategic initiatives
  • 8.2.3. Merck & Co., Inc.
    • 8.2.3.1. Company overview
    • 8.2.3.2. Financial performance
    • 8.2.3.3. Product benchmarking
    • 8.2.3.4. Strategic initiatives
  • 8.2.4. AbbVie Inc.
    • 8.2.4.1. Company overview
    • 8.2.4.2. Financial performance
    • 8.2.4.3. Product benchmarking
    • 8.2.4.4. Strategic initiatives
  • 8.2.5. Novartis AG
    • 8.2.5.1. Company overview
    • 8.2.5.2. Financial performance
    • 8.2.5.3. Product benchmarking
    • 8.2.5.4. Strategic initiatives
  • 8.2.6. Bayer AG
    • 8.2.6.1. Company overview
    • 8.2.6.2. Financial performance
    • 8.2.6.3. Product benchmarking
    • 8.2.6.4. Strategic initiatives
  • 8.2.7. AstraZeneca plc
    • 8.2.7.1. Company overview
    • 8.2.7.2. Financial performance
    • 8.2.7.3. Product benchmarking
    • 8.2.7.4. Strategic initiatives
  • 8.2.8. Corium International, Inc
    • 8.2.8.1. Company overview
    • 8.2.8.2. Financial performance
    • 8.2.8.3. Product benchmarking
    • 8.2.8.4. Strategic initiatives
  • 8.2.9. Alkermes plc
    • 8.2.9.1. Company overview
    • 8.2.9.2. Financial performance
    • 8.2.9.3. Product benchmarking
    • 8.2.9.4. Strategic initiatives
  • 8.2.10. Amneal Pharmaceuticals
    • 8.2.10.1. Company overview
    • 8.2.10.2. Financial performance
    • 8.2.10.3. Product benchmarking
    • 8.2.10.4. Strategic initiatives